Literature DB >> 27215428

Prostate cancer: ADT after radical prostatectomy - when and how?

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27215428     DOI： 10.1038/nrurol.2016.97

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Authors:  Christian Carrie; Ali Hasbini; Guy de Laroche; Pierre Richaud; Stéphane Guerif; Igor Latorzeff; Stéphane Supiot; Mathieu Bosset; Jean-Léon Lagrange; Véronique Beckendorf; François Lesaunier; Bernard Dubray; Jean-Philippe Wagner; Tan Dat N'Guyen; Jean-Philippe Suchaud; Gilles Créhange; Nicolas Barbier; Muriel Habibian; Céline Ferlay; Philippe Fourneret; Alain Ruffion; Sophie Dussart
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

2.  Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Authors:  Gillian M Duchesne; Henry H Woo; Julie K Bassett; Steven J Bowe; Catherine D'Este; Mark Frydenberg; Madeleine King; Leo Ledwich; Andrew Loblaw; Shawn Malone; Jeremy Millar; Roger Milne; Rosemary G Smith; Nigel Spry; Martin Stockler; Rodney A Syme; Keen Hun Tai; Sandra Turner
Journal:  Lancet Oncol       Date:  2016-05-04       Impact factor: 41.316
  2 in total
  1 in total

Review 1.  Patterns of indolence in prostate cancer (Review).

Authors:  Minas Sakellakis; Laura Jacqueline Flores; Sumankalai Ramachandran
Journal:  Exp Ther Med       Date:  2022-03-28       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.